Last reviewed · How we verify
Cyclophosphamid
At a glance
| Generic name | Cyclophosphamid |
|---|---|
| Also known as | Anti-thymocyte globulin, Cyclophosphamide, huanlinxianan, Indoxan, CTX |
| Sponsor | Zhejiang University |
| Target | Cytochrome P450 3A4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Acute lymphoid leukemia, disease
- Acute monocytic leukemia
- Acute myelogenous leukemia
- Adenocarcinoma of the ovary
- Burkitt's lymphoma
- Carcinoma of breast
- Chronic lymphoid leukemia, disease
- Chronic myeloid leukemia
- Histiocytic lymphoma
- Hodgkin's disease
- Malignant lymphoma
- Mixedcell type lymphoma
- Multiple myeloma
- Mycosis fungoides
- Neuroblastoma
- Retinoblastoma
- Systemic AL amyloidosis
- Treatment prior to tumor-specific T-cell infusion therapy
Common side effects
- Neutropenia
- Febrile neutropenia
- Fever
- Alopecia
- Nausea
- Vomiting
- Diarrhea
- Myelosuppression
- Fatigue
- Headache
- Malaise
- Pain
Serious adverse events
- Cardiac arrest
- Cardiac failure
- Cardiomyopathy
- Myocardial infarction
- Hemorrhagic cystitis
- Renal failure
- Sepsis
- Acute leukemia
- Bladder cancer
- Veno-occlusive liver disease
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies (PHASE2)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (PHASE1, PHASE2)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclophosphamid CI brief — competitive landscape report
- Cyclophosphamid updates RSS · CI watch RSS
- Zhejiang University portfolio CI